These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 31999935)
21. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers. Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263 [TBL] [Abstract][Full Text] [Related]
22. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic. Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248 [TBL] [Abstract][Full Text] [Related]
23. Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer. Yoneda K; Kuwata T; Kanayama M; Mori M; Kawanami T; Yatera K; Ohguri T; Hisaoka M; Nakayama T; Tanaka F Br J Cancer; 2019 Sep; 121(6):490-496. PubMed ID: 31388183 [TBL] [Abstract][Full Text] [Related]
24. Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients. Shimoda Y; Yoshida T; Shirasawa M; Mizuno T; Jo H; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Yatabe Y; Ohe Y; Motoi N Anticancer Res; 2021 Nov; 41(11):5739-5747. PubMed ID: 34732447 [TBL] [Abstract][Full Text] [Related]
25. Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions. Teng F; Meng X; Wang X; Yuan J; Liu S; Mu D; Zhu H; Kong L; Yu J Oncotarget; 2016 Sep; 7(39):64318-64329. PubMed ID: 27602763 [TBL] [Abstract][Full Text] [Related]
26. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Mansfield AS; Aubry MC; Moser JC; Harrington SM; Dronca RS; Park SS; Dong H Ann Oncol; 2016 Oct; 27(10):1953-8. PubMed ID: 27502709 [TBL] [Abstract][Full Text] [Related]
27. Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype. Takada K; Toyokawa G; Kinoshita F; Jogo T; Kohashi K; Wakasu S; Ono Y; Tanaka K; Oba T; Osoegawa A; Tagawa T; Azuma K; Okamoto I; Shimokawa M; Oda Y; Mori M J Cancer Res Clin Oncol; 2020 Oct; 146(10):2639-2650. PubMed ID: 32405745 [TBL] [Abstract][Full Text] [Related]
28. PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes. Liu B; Arakawa Y; Yokogawa R; Tokunaga S; Terada Y; Murata D; Matsui Y; Fujimoto KI; Fukui N; Tanji M; Mineharu Y; Minamiguchi S; Miyamoto S PLoS One; 2018; 13(4):e0194594. PubMed ID: 29617441 [TBL] [Abstract][Full Text] [Related]
29. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872 [TBL] [Abstract][Full Text] [Related]
30. Programmed death-1 receptor (PD-1) and PD-ligand-1 (PD-L1) expression in non-small cell lung cancer and the immune-suppressive effect of anaerobic glycolysis. Giatromanolaki A; Koukourakis IM; Balaska K; Mitrakas AG; Harris AL; Koukourakis MI Med Oncol; 2019 Jul; 36(9):76. PubMed ID: 31342270 [TBL] [Abstract][Full Text] [Related]
31. Aligning digital CD8 Conde E; Caminoa A; Dominguez C; Calles A; Walter S; Angulo B; Sánchez E; Alonso M; Jimenez L; Madrigal L; Hernando F; Sanz-Ortega J; Jimenez B; Garrido P; Paz-Ares L; de Castro J; Hernandez S; Lopez-Rios F Histopathology; 2018 Jan; 72(2):270-284. PubMed ID: 28815764 [TBL] [Abstract][Full Text] [Related]
32. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma. Del C Monroig-Bosque P; Driver B; Morales-Rosado JA; Deavers M; Tacha D; Bernicker E; Cagle PT; Miller RA Arch Pathol Lab Med; 2018 Nov; 142(11):1388-1393. PubMed ID: 29431467 [TBL] [Abstract][Full Text] [Related]
33. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer. Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649 [TBL] [Abstract][Full Text] [Related]
34. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis. Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017 [TBL] [Abstract][Full Text] [Related]
35. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811 [TBL] [Abstract][Full Text] [Related]
36. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Berghoff AS; Ricken G; Widhalm G; Rajky O; Dieckmann K; Birner P; Bartsch R; Höller C; Preusser M Histopathology; 2015 Jan; 66(2):289-99. PubMed ID: 25314639 [TBL] [Abstract][Full Text] [Related]